Last updated: February 26, 2024
Sponsor: Steen Hvitfeldt Poulsen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Amyloidosis
Circulation Disorders
Treatment
N/AClinical Study ID
NCT06291805
1-10-72-189-23
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Group 1: wtATTR-CM patients Inclusion Criteria:
- Patients > 18 years diagnosed with ATTRwt-CM by:
- endomyocardial biopsy
- DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due togenetic testing.
- Informed oral and written consent
Exclusion
Exclusion Criteria:
- AL amyloidosis (light-chain amyloidosis).
- Myelomatosis
- Waldenström macroglobulinemia Group 2: Control group Inclusion Criteria:
- Patients > 18 years
- Informed oral and written consent Exclusion Criteria:
- Known cardiovascular disease including ischemic heart disease, heart failure, atrialfibrillation, presence of a pacemaker, or malignant hypertension. Well-controlledhypertension is acceptable.
- Suspicion of cardiac amyloidosis assessed through clinical history, physicalexamination, ECG, and echocardiography focusing on "red flags":
- Echocardiography with:
- Myocardial hypertrophy (septum >11 mm)
- Apical sparing in LV-GLS
- Infiltrative changes in the right ventricle free wall, thickened atrioventricularvalves, or thickened atrial septum
- Symptoms of polyneuropathy
- Low voltage on ECG or discrepancy between left ventricular thickness and ECG amplitudeindicative of low voltage
- Atrioventricular block (AV block)
- Bilateral carpal tunnel syndrome
- Surgery for spinal stenosis
- Elevated troponin I or NT-pro-BNP
Study Design
Total Participants: 120
Study Start date:
February 20, 2024
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Aarhus University Hospital
Aarhus, Arrhus N 8200
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.